Mark to Market
Mark to Market
Mint - HT Smartcast
113: After slow IPO, Gland Pharma finds more takers in secondary markets
7 minutes Posted Nov 26, 2020 at 8:22 am.
0:00
7:33
Download MP3
Show notes
Whoever stuck their neck out in the Gland Pharma IPO is already sitting on decent gains. For an issue that offered full allotment for every application in the non-institutional category, it’s been among the best-performing IPOs for investors. Tune in here for more details.
Learn more about your ad choices. Visit megaphone.fm/adchoices